Adjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support

Size: px
Start display at page:

Download "Adjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support"

Transcription

1 Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no input in its content. 1

2 Conflicts of Interest Dr. Cohen has received honoraria from Bristol-Myers Squibb and Sanofi- Aventis. He has consulted for Amgen. Heterogeneity Primary sites Lip Oral cavity Oropharynx Hypopharynx Larynx Paranasal sinuses Nasopharynx Salivary glands 95% are squamous cell carcinomas Anatomic Sites and Subsides of the Head and Neck 2

3 2008, US: new cases 7600 deaths Worldwide: new cases Incidence 6th leading cause of death M:F = 2:1 Survival Overall 50% long-term survival Recurrence Second malignancies Co-morbidities 3

4 Staging Stage at Diagnosis Stage IVc Stage I, II Stage III, IVa, IVb TREATED WITH CURATIVE INTENT Risk Factors Age (majority of patients >50 years old) Tobacco Alcohol Viral Epstein-Barr virus (NPC) HPV (oropharynx) Hereditary (rare): Family history increases risk (3.5X) Rare genetic syndromes, e.g. Fanconi s Anemia 4

5 Cure is Paramount, QoL is Important List, M. A. et al. J Clin Oncol; 18: Post-Op CRT 5

6 EORTC and RTOG 9501 Phase III Trials: Adjuvant RT ± Concomitant Cisplatin Resectable SCC Oral cavity, oropharynx, hypopharynx, larynx Stage IIIIV (EORTC), high risk (RTOG) Previously untreated N=334 (EORTC) N=459 (RTOG) Surgery R A N D O M I Z E Adjuvant CRT RT Cisplatin (100 mgm 2, d1,22,43) RT Alone EORTC: 66 Gy over 6.5 wks RTOG: Gy over wks Bernier. N Engl J Med. 2004;350:1945; Cooper. N Engl J Med. 2004;350:1937. Post-Op CRT EORTC patients Primary endpoint: PFS Positive margins 28% > 2 LN 54% ECS 57% RTOG patients Primary endpoint: LRC Positive margins 18% > 2 LN or ECS 82% 6

7 Post-Op CRT Phase 3 Studies * p<0.05 EORTC RTOG (Cooper, (Bernier, 2004) 2004) CRT RT CRT RT Incidence of Locoregional Failure 18% 31%* 16% 29%* Incidence of Metastases 21% 25% 20% 23% Grade >3 Adverse Effects 41% 21%* 77% 34%* 5-Year Estimated PFS 47% 36%* NR 5-Year Estimated OS 53% 40%* HR=0.84 ( ), P= Year Locoregional 82% 72%* Control Rate NR HR=0.78 (0.61- DFS 0.99)* EORTC and RTOG 9501 OS (EORTC) OS (RTOG) P=0.02 P=0.19 Months After Randomization Pooled Analysis: The most significant prognostic factors for poor outcome were ECS and positive margins Subjects with 2 or more lymph nodes without ECS, did not seem to benefit 7

8 Targeting EGFR in SCCHN EGFR in almost universally expressed in SCCHN Expression has been linked to poor prognosis Inhibition of EGFR by monoclonal antibodies or small molecules: effective preclinically demonstrate reproducible clinical activity Phase II Randomized Trial of Postoperative Chemoradiotherapy Plus Cetuximab for High-Risk Squamous Cell Carcinoma of the Head and Neck (RTOG 0234) M. S. Kies 1, J. Harris 2, M. Z. Rotman 3, J. N. Myers 1, R. L. Foote 4, M. Machtay 5, D. Khuntia 6, W. L. Straube 7, K. K. Ang 1, and P. M. Harari 8 1 UT MD Anderson Cancer Center, Houston, TX, 2 American College of Radiology-Radiation Radiation Therapy Oncology Group, Philadelphia, PA, 3 SUNY Downstate Medical Center, Brooklyn, NY, 4 Mayo Clinic, Rochester, MN, 5 Jefferson Medical College, Philadelphia, PA, 6 University of Wisconsin, Madison, WI, 7 Washington University, St. Louis, MO, 8 University of Wisconsin School of Medicine, Madison, WI Supported by RTOG U10 CA21661, CCOP U10 CA37422 and ATC U24 CA Supported by RTOG U10 CA21661, CCOP U10 CA37422 and ATC U24 CA grants from NCI. Additional support was provided by Sanofi-Aventis and Bristol- Myers Squibb

9 Objectives Primary: A randomized phase II study of chemoradiotherapy with cetuximab, in high-risk postoperative head and neck patients, to evaluate disease-free survival relative to chemoradiation of RTOG Treatment Schema S T R A T I F Y Zubrod Score Risk Category a 1. Positive margins 2. High risk ( 2 positive nodes or extranodal capsular spread) R A N D O M I Z E Arm 1 Week 1: Cetuximab 400mgm2 Weeks 2-7: 60 Gy (2 Gyday) - CDDP 30mgm2 + cetuximab 250 mgm2 Arm 2 Week 1: Cetuximab 400 mgm2 Weeks 2-7: 60 Gy (2 Gyday) - Docetaxel 15 mgm2 + cetuximab 250 mgm2 Gross total resection must be completed within 7 weeks of randomization. a If both risk factors are present, patient will be stratified as positive margins

10 RTOG 0234 Eligibility Stage III IV SCCHN sp gross total surgical resection Must have positive resection margins and or 2 nodal metastases and or ECS Performance Status Adverse Events Grades 3 5 (%) RT CDDP RT Doc cetuximab cetuximab (n = 97) (n = 106) Hypersensitivity Bone Marrow Infection Metabolic Mucositis Rash Respiratory Overall (%)

11 Disease-Free Survival RT CDDPcetuximab vs RTOG Disease-Free Survival (%) RT+CDDP+Cet HR (95% CI) 0.85 (0.60, 1.21) 1-sided log-rank p= RT+CDDP Patients at Risk RTOG 0234 RTOG Years after Registration Disease-Free Survival RT Doccetuximab vs RTOG Disease-Free Survival (%) RT+Doc+Cet HR (95% CI) 0.72 (0.50, 1.02) 1-sided log-rank p= RT+CDDP Patients at Risk RTOG 0234 RTOG Years after Registration

12 Erlotinib Prevention of Oral Cancer (EPOC) IEN alone Proportion of cases not developing SOM (%) IEN plus cancer history MDACC (Papadimitrakopoulou, Lippman, Mao et al) U Chicago (Cohen et al) MSKCC (Boyle et al) Emory (Shin et al) P01 CA

13 Randomized Phase II Trial of Everolimus Versus Placebo as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN) Study Design Screening Randomization (n=160) Treatment Enrollment -assess eligibility -sign ICF -obtain tissue Curative Intent Therapy 8-16 Weeks RANDOMIZE Everolimus 10mg OD Primary Endpoint: 2-year PFS Placebo Confirm NED Double-blinded Stratification: Treatment Center Stage (IVa vs. IVb) 13

14 Conclusions High risk post-operative patients benefit from the addition of chemotherapy to radiotherapy The decision to undergo surgery first should be undertaken with care and does not represent the standard of care for most head and neck cancer patients. New therapies are being introduced in an effort to improve outcomes further. We thank Eli Lilly for their support of this program. 14

Pre- Versus Post-operative Radiotherapy

Pre- Versus Post-operative Radiotherapy Postoperative Radiation and Chemoradiation: Indications and Optimization of Practice Dislosures Clinical trial support from Genentech Inc. Sue S. Yom, MD, PhD Associate Professor UCSF Radiation Oncology

More information

The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer

The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer Robert I. Haddad, Guilherme Rabinowits, Roy B. Tishler,

More information

Locally advanced head and neck cancer

Locally advanced head and neck cancer Locally advanced head and neck cancer Radiation Oncology Perspective Petek Erpolat, MD Gazi University, Turkey Definition and Management of LAHNC Stage III or IV cancers generally include larger primary

More information

Oral Cavity Cancer Combined modality therapy

Oral Cavity Cancer Combined modality therapy Oral Cavity Cancer Combined modality therapy Dr. Christos CHRISTOPOULOS Radiation Oncologist Head and Neck Cancers Centre Hospitalier Universitaire (C.H.U.) de Limoges, France Disclosure slide I have no

More information

De-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist

De-Escalate Trial for the Head and neck NSSG. Dr Eleanor Aynsley Consultant Clinical Oncologist De-Escalate Trial for the Head and neck NSSG Dr Eleanor Aynsley Consultant Clinical Oncologist 3 HPV+ H&N A distinct disease entity Leemans et al., Nature Reviews, 2011 4 Good news Improved response to

More information

Head and Neck Cancer:

Head and Neck Cancer: Head and Neck Cancer: Robert Haddad M.D. Clinical Director Head and Neck Oncology Program Dana Farber Cancer Institute Boston, MA Predictive Biomarkers: HPV Abstract 6003: Survival Outcomes By HPV Status

More information

SAMO MASTERCLASS HEAD & NECK CANCER. Nicolas Mach, PD Geneva University Hospital

SAMO MASTERCLASS HEAD & NECK CANCER. Nicolas Mach, PD Geneva University Hospital SAMO MASTERCLASS HEAD & NECK CANCER Nicolas Mach, PD Geneva University Hospital Epidemiology Prevention Best treatment for localized disease Best treatment for relapsed or metastatic disease Introduction

More information

Accepted 28 April 2005 Published online 13 September 2005 in Wiley InterScience ( DOI: /hed.

Accepted 28 April 2005 Published online 13 September 2005 in Wiley InterScience (  DOI: /hed. DEFINING RISK LEVELS IN LOCALLY ADVANCED HEAD AND NECK CANCERS: A COMPARATIVE ANALYSIS OF CONCURRENT POSTOPERATIVE RADIATION PLUS CHEMOTHERAPY TRIALS OF THE EORTC (#22931) AND RTOG (#9501) Jacques Bernier,

More information

Emerging Role of Immunotherapy in Head and Neck Cancer

Emerging Role of Immunotherapy in Head and Neck Cancer Emerging Role of Immunotherapy in Head and Neck Cancer Jared Weiss, MD Associate Professor of Medicine and Section Chief of Thoracic and Head/Neck Oncology UNC Lineberger Comprehensive Cancer Center Copyright

More information

Squamous Cell Carcinoma of the Oral Cavity: Radio therapeutic Considerations

Squamous Cell Carcinoma of the Oral Cavity: Radio therapeutic Considerations Squamous Cell Carcinoma of the Oral Cavity: Radio therapeutic Considerations Troy G. Scroggins Jr. MD Chairman, Department of Radiation Oncology Ochsner Health Systems 1 Association of Postoperative Radiotherapy

More information

Multimodular treatment in Head and Neck Squamous Cell Carcinoma (HNSCC)

Multimodular treatment in Head and Neck Squamous Cell Carcinoma (HNSCC) Multimodular treatment in Head and Neck Squamous Cell Carcinoma (HNSCC) Amanda Psyrri, MD,FACP Attikon University Hospital Athens, Greece Learning objectives After reading and reviewing this material,

More information

Clinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221. Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS

Clinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221. Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS Clinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221 Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS 1 Disclosure I have no conflicts of interest to disclose 2 Robotic H&N

More information

Therapy of Locally Advanced Head and Neck Cancer: State of the Art

Therapy of Locally Advanced Head and Neck Cancer: State of the Art Therapy of Locally Advanced Head and Neck Cancer: State of the Art Barbara Burtness, MD Chief, Head and Neck ncology Medical ncology Co-Leader Senior Member Fox Chase Cancer Center Philadelphia, PA Therapy

More information

Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer

Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer Simultaneous Integrated Boost or Sequential Boost in the Setting of Standard Dose or Dose De-escalation for HPV- Associated Oropharyngeal Cancer Dawn Gintz, CMD, RTT Dosimetry Coordinator of Research and

More information

Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck. Mei Tang, MD

Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck. Mei Tang, MD Neoadjuvant Chemotherapy in Locally Advanced Squamous Cell Cancer of Head and Neck Mei Tang, MD Head and Neck Cancer Worldwide New cases : 644,000 Cancer deaths: 350,000 About 5% of all cancers Local Recurrence:

More information

New Agents for Head and Neck Cancer. Ezra Cohen, MD Associate Professor of Medicine University of Chicago Chicago, IL

New Agents for Head and Neck Cancer. Ezra Cohen, MD Associate Professor of Medicine University of Chicago Chicago, IL New Agents for Head and Neck Cancer Ezra Cohen, MD Associate Professor of Medicine University of Chicago Chicago, IL Disclosure Dr. Cohen has the following relevant financial relationships with commercial

More information

Post-Operative Concurrent Chemoradiation with Mitomycin-C for Advanced Head and Neck Cancer

Post-Operative Concurrent Chemoradiation with Mitomycin-C for Advanced Head and Neck Cancer Yale University EliScholar A Digital Platform for Scholarly Publishing at Yale Yale Medicine Thesis Digital Library School of Medicine 2006 Post-Operative Concurrent Chemoradiation with Mitomycin-C for

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium cetuximab 2mg/ml intravenous infusion (Erbitux ) (279/06) MerckKGaA No 9 June 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product

More information

Head and Neck cancer

Head and Neck cancer Head and Neck cancer Medical Oncologist s Role in Multidisciplinary Teams - Focus on Adjuvant & Neo-adjuvant Therapy - Hye Ryun Kim, M.D. Yonsei Cancer Center, Medical Oncology Contents I. Introduction

More information

Combined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago

Combined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy

More information

HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium

HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV

More information

The International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology

The International Federation of Head and Neck Oncologic Societies. Current Concepts in Head and Neck Surgery and Oncology The International Federation of Head and Neck Oncologic Societies Current Concepts in Head and Neck Surgery and Oncology www.ifhnos.net The International Federation of Head and Neck Oncologic Societies

More information

Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK

Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK Lead Group Log Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK Cervical Cancer treatment Treatment planning should be made on a multidisciplinary

More information

CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER

CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER Jean-Pascal Machiels Department of medical oncology Institut I Roi Albert II Cliniques universitaires Saint-Luc Université catholique de Louvain, Brussels,

More information

Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist

Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage

More information

Clinical Policy: Cetuximab (Erbitux) Reference Number: PA.CP.PHAR.317

Clinical Policy: Cetuximab (Erbitux) Reference Number: PA.CP.PHAR.317 Clinical Policy: (Erbitux) Reference Number: PA.CP.PHAR.317 Effective Date: 01/18 Last Review Date: 11/17 Coding Implications Revision Log Description The intent of the criteria is to ensure that patients

More information

Accepted 20 April 2009 Published online 25 June 2009 in Wiley InterScience (www.interscience.wiley.com). DOI: /hed.21179

Accepted 20 April 2009 Published online 25 June 2009 in Wiley InterScience (www.interscience.wiley.com). DOI: /hed.21179 ORIGINAL ARTICLE DOCETAXEL, CISPLATIN, AND FLUOROURACIL INDUCTION CHEMOTHERAPY FOLLOWED BY ACCELERATED FRACTIONATION/CONCOMITANT BOOST RADIATION AND CONCURRENT CISPLATIN IN PATIENTS WITH ADVANCED SQUAMOUS

More information

Nasopharynx Cancer. 1 Feb Presenters: Dr Raghav Murali-Ganesh (Radiation Oncology Registrar) Dr Peter Luk (Pathology Registrar)

Nasopharynx Cancer. 1 Feb Presenters: Dr Raghav Murali-Ganesh (Radiation Oncology Registrar) Dr Peter Luk (Pathology Registrar) Nasopharynx Cancer 1 Feb 2016 Presenters: Dr Raghav Murali-Ganesh (Radiation Oncology Registrar) Dr Peter Luk (Pathology Registrar) Expert Panels Prof Mo Mo Tin Prof Michael Boyer Dr Raewyn Campbell Prof

More information

Non-surgical treatment for locally advanced head and neck squamous cell carcinoma: beyond the upper limit

Non-surgical treatment for locally advanced head and neck squamous cell carcinoma: beyond the upper limit Editorial Non-surgical treatment for locally advanced head and neck squamous cell carcinoma: beyond the upper limit Hiroto Ishiki, Satoru Iwase Department of Palliative Medicine, The Institute of Medical

More information

Protocol of Radiotherapy for Head and Neck Cancer

Protocol of Radiotherapy for Head and Neck Cancer 106 年 12 月修訂 Protocol of Radiotherapy for Head and Neck Cancer Indication of radiotherapy Indication of definitive radiotherapy with or without chemotherapy (1) Resectable, but medically unfit, or high

More information

TREATMENT TIME & TOBACCO: TWIN TERRORS Of H&N Therapy

TREATMENT TIME & TOBACCO: TWIN TERRORS Of H&N Therapy TREATMENT TIME & TOBACCO: TWIN TERRORS Of H&N Therapy Anurag K. Singh, MD Professor of Medicine University at Buffalo School of Medicine Professor of Oncology Director of Radiation Research Roswell Park

More information

Neoplasie del laringe Diagnosi e trattamento

Neoplasie del laringe Diagnosi e trattamento Neoplasie del laringe Diagnosi e trattamento Venerdì 22 maggio 2015 Alessandria Trattamenti non chirurgici: Preservazione d organo, malattia localmente avanzata Marco C Merlano A.O. S.Croce e Carle, Ospedale

More information

Head and Neck Reirradiation: Perils and Practice

Head and Neck Reirradiation: Perils and Practice Head and Neck Reirradiation: Perils and Practice David J. Sher, MD, MPH Department of Radiation Oncology Dana-Farber Cancer Institute/ Brigham and Women s Hospital Conflicts of Interest No conflicts of

More information

Organ-Preservation Strategies in head and neck cancer. Teresa Bonfill Abella Oncologia Mèdica Parc Taulí Sabadell. Hospital Universitari

Organ-Preservation Strategies in head and neck cancer. Teresa Bonfill Abella Oncologia Mèdica Parc Taulí Sabadell. Hospital Universitari Organ-Preservation Strategies in head and neck cancer Teresa Bonfill Abella Oncologia Mèdica Parc Taulí Sabadell. Hospital Universitari Larynx Hypopharynx The goal of treatment is to achieve larynx preservation

More information

Recent Advances & Ongoing Challenges in Head & Neck Cancers

Recent Advances & Ongoing Challenges in Head & Neck Cancers Recent Advances & Ongoing Challenges in Head & Neck Cancers Robert Haddad, MD Disease Center Leader Head and Neck Oncology Program Dana Farber Cancer Institute Harvard Medical School Boston, MA Disclosures

More information

3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014

3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014 Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R

More information

GCIG Rare Tumour Brainstorming Day

GCIG Rare Tumour Brainstorming Day GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial

More information

MANAGEMENT OF LOCALLY ADVANCED OROPHARYNGEAL CANER: HPV AND NON-HPV MEDIATED CANCERS

MANAGEMENT OF LOCALLY ADVANCED OROPHARYNGEAL CANER: HPV AND NON-HPV MEDIATED CANCERS MANAGEMENT OF LOCALLY ADVANCED OROPHARYNGEAL CANER: HPV AND NON-HPV MEDIATED CANCERS Kyle Arneson, MD PhD Avera Medical Group Radiation Oncology Avera Cancer Institute 16 th Annual Oncology Symposium September

More information

Triple-Modality Treatment in Patients With Advanced Stage Tonsil Cancer

Triple-Modality Treatment in Patients With Advanced Stage Tonsil Cancer Triple-Modality Treatment in Patients With Advanced Stage Tonsil Cancer Dylan F. Roden, MD, MPH 1,2 ; David Schreiber, MD 2,3 ; and Babak Givi, MD 1,2 BACKGROUND: Concurrent chemoradiation (CCRT) and upfront

More information

Laryngeal Preservation Using Radiation Therapy. Chemotherapy and Organ Preservation

Laryngeal Preservation Using Radiation Therapy. Chemotherapy and Organ Preservation 1 Laryngeal Preservation Using Radiation Therapy 1903: Schepegrell was the first to perform radiation therapy for the treatment of laryngeal cancer Conventional external beam radiation produced disappointing

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 11: June 15, 2011 The Clinical Research E-News Reminder: CRA Quarterly Meeting, Philadelphia, PA: 10-11am on Wednesday June 22nd- Virtual Meeting: dial information attached in a separate

More information

GASTRIC & PANCREATIC CANCER

GASTRIC & PANCREATIC CANCER GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org

More information

Gastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.

Gastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D. Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation

More information

Thomas Gernon, MD Otolaryngology THE EVOLVING TREATMENT OF SCCA OF THE OROPHARYNX

Thomas Gernon, MD Otolaryngology THE EVOLVING TREATMENT OF SCCA OF THE OROPHARYNX Thomas Gernon, MD Otolaryngology THE EVOLVING TREATMENT OF SCCA OF THE OROPHARYNX Disclosures I have nothing to disclose. 3 Changing Role of Surgery N=42,688 Chen Ay et al. Larygoscope. 2007; 117:16-21

More information

Oral cavity cancer Post-operative treatment

Oral cavity cancer Post-operative treatment Oral cavity cancer Post-operative treatment Dr. Christos CHRISTOPOULOS Radiation Oncologist Centre Hospitalier Universitaire (C.H.U.) de Limoges, France Important issues RT -techniques Patient selection

More information

Radio(chemo)therapy for head and neck cancer HNSCC: indications and modalities Prof. dr. Sandra Nuyts Radiotherapy-Oncology

Radio(chemo)therapy for head and neck cancer HNSCC: indications and modalities Prof. dr. Sandra Nuyts Radiotherapy-Oncology Radio(chemo)therapy for head and neck cancer HNSCC: indications and modalities Prof. dr. Sandra Nuyts Radiotherapy-Oncology March 2018 > Half million new cases HNC/year in world 50-60% cured not cured

More information

Physician to Physician AJCC 8 th Edition. Head and Neck. Summary of Changes. AJCC Cancer Staging Manual, 7 th Ed. Head and Neck Chapters

Physician to Physician AJCC 8 th Edition. Head and Neck. Summary of Changes. AJCC Cancer Staging Manual, 7 th Ed. Head and Neck Chapters Physician to Physician Head and Neck William M. Lydiatt, MD Chair of Surgery Nebraska Methodist Hospital Clinical Professor of Surgery, Creighton University Validating science. Improving patient care.

More information

UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER

UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review

More information

and neck cancers, 2018

and neck cancers, 2018 Emerging systemic treatments for head and neck cancers, 2018 A. DIMITRIOS COLEVAS, MD PROFESSOR OF MEDICINE (ONCOLOGY) AND, BY COURTESY, OF OTOLARYNGOLOGY - HEAD AND NECK SURGERY AT THE STANFORD UNIVERSITY

More information

State of the Art: Management of Squamous Cell Carcinoma of the Head and Neck. Raul Giglio

State of the Art: Management of Squamous Cell Carcinoma of the Head and Neck. Raul Giglio State of the Art: Management of Squamous Cell Carcinoma of the Head and Neck Raul Giglio Disclosures Nothing to disclose SCCHN Outline 1. General considerations: MTD 2. Epidemiology 3. Locoregional disease

More information

Immunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University

Immunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,

More information

State of the art for radiotherapy of SCCHN

State of the art for radiotherapy of SCCHN State of the art for radiotherapy of SCCHN Less side effects Cured More organ & function preservation Head & neck cancer = 42 000 new cases / year in Europe Not cured Local failure Distant failure More

More information

RT +/- Surgery. Concurrent ChemoRT +/- Surgery

RT +/- Surgery. Concurrent ChemoRT +/- Surgery Molecular targeted approaches to head and neck cancer Lillian L. Siu Department of Medical Oncology & Hematology Princess Margaret Hospital, University of Toronto Locally Advanced HNSCC Locally Advanced

More information

New Paradigms for Treatment of. Erminia Massarelli, MD, PHD, MS Clinical Associate Professor

New Paradigms for Treatment of. Erminia Massarelli, MD, PHD, MS Clinical Associate Professor New Paradigms for Treatment of Head and Neck cancers Erminia Massarelli, MD, PHD, MS Clinical Associate Professor City of Hope Disclosure Statement Grant/Research Support frommerck Bristol Grant/Research

More information

Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We

Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David

More information

MANAGEMENT OF CA HYPOPHARYNX

MANAGEMENT OF CA HYPOPHARYNX MANAGEMENT OF CA HYPOPHARYNX GENERAL TREATMENT RECOMMENDATIONS BASED ON HYPOPHARYNX TUMOR STAGE For patients presenting with early-stage definitive radiotherapy alone or voice-preserving surgery are viable

More information

Nasopharyngeal Cancer:Role of Chemotherapy

Nasopharyngeal Cancer:Role of Chemotherapy Nasopharyngeal Cancer:Role of Chemotherapy PANAGIOTIS KATSAOUNIS Medical Oncologist IASO GENERAL HOSPITAL Athens, 16/9/2017 2 nd Hellenic Multidisciplinary Conference on Head and Neck Cancer INTRODUCTION

More information

Management of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT

Management of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT Management of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan Kettering Cancer Center Disclosure Consulting

More information

Quality Variation and Clinical Impact in Head and Neck IMRT

Quality Variation and Clinical Impact in Head and Neck IMRT Quality Variation and Clinical Impact in Head and Neck IMRT 6 th IMRT Symposium, New York Sep. 20, 2010 K.S. Clifford Chao, MD Chairman, Combined Radiation Oncology, New York Presbyterian Hospital Chairman,

More information

Highlights in head and neck cancer

Highlights in head and neck cancer Special Edition Highlights in head and neck cancer P. Specenier, MD, PhD (Belg J Med Oncol 201;9:168-72) Management of locoregional lymph nodes The optimal management of the regional lymph nodes was studied

More information

Heterogeneity of N2 disease

Heterogeneity of N2 disease Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity

More information

EGFR inhibitors in NSCLC

EGFR inhibitors in NSCLC Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance

More information

STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER

STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical

More information

Lymph node ratio as a prognostic factor in head and neck cancer patients

Lymph node ratio as a prognostic factor in head and neck cancer patients Chen et al. Radiation Oncology (2015) 10:181 DOI 10.1186/s13014-015-0490-9 RESEARCH Open Access Lymph node ratio as a prognostic factor in head and neck cancer patients Chien-Chih Chen 1*, Jin-Ching Lin

More information

Self-Assessment Module 2016 Annual Refresher Course

Self-Assessment Module 2016 Annual Refresher Course LS16031305 The Management of s With r. Lin Learning Objectives: 1. To understand the changing demographics of oropharynx cancer, and the impact of human papillomavirus on overall survival and the patterns

More information

Head and NeckCancer: multi-modal therapeuticintegration

Head and NeckCancer: multi-modal therapeuticintegration Head and NeckCancer: multi-modal therapeuticintegration P. Ponticelli, L. Lastrucci, R. De Majo, A. Rampini U.O.C. Radioterapia Ospedale S. Donato ASL 8 -AREZZO Summary Biological considerations Clinical

More information

Sequencing Chemo with Radiation therapy Locally Advanced Head and Neck Cancer. Dr P Vijay Anand Reddy Director Apollo Cancer Hospital

Sequencing Chemo with Radiation therapy Locally Advanced Head and Neck Cancer. Dr P Vijay Anand Reddy Director Apollo Cancer Hospital Sequencing Chemo with Radiation therapy Locally Advanced Head and Neck Cancer Dr P Vijay Anand Reddy Director Apollo Cancer Hospital H&N Ca - Disease Burden 15-20% of all cancers in India, 8% worldwide

More information

ACR Appropriateness Criteria Adjuvant Therapy for Resected Squamous Cell Carcinoma of the Head and Neck EVIDENCE TABLE

ACR Appropriateness Criteria Adjuvant Therapy for Resected Squamous Cell Carcinoma of the Head and Neck EVIDENCE TABLE 1. Johnson JT, Barnes EL, Myers EN, Schramm VL, Jr., Borochovitz D, Sigler BA. The extracapsular spread of tumors in cervical node metastasis. Arch Otolaryngol 1981; 107(1):75-79.. Snow GB, Annyas AA,

More information

Head and Neck Cancer in FA: Risks, Prevention, Screening, & Treatment Options David I. Kutler, M.D., F.A.C.S.

Head and Neck Cancer in FA: Risks, Prevention, Screening, & Treatment Options David I. Kutler, M.D., F.A.C.S. Head and Neck Cancer in FA: Risks, Prevention, Screening, & Treatment Options David I. Kutler, M.D., F.A.C.S. Associate Professor Division of Head and Neck Surgery Department of Otolaryngology-Head and

More information

Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice?

Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice? Cent. Eur. J. Med. 9(2) 2014 279-284 DOI: 10.2478/s11536-013-0154-9 Central European Journal of Medicine Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice? Jacopo Giuliani* 1, Marina

More information

RADIATION THERAPY ONCOLOGY GROUP RTOG 0234

RADIATION THERAPY ONCOLOGY GROUP RTOG 0234 RADIATION THERAPY ONCOLOGY GROUP RTOG 0234 A PHASE II RANDOMIZED TRIAL OF SURGERY FOLLOWED BY CHEMORADIOTHERAPY PLUS C225 (CETUXIMAB) FOR ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK Pathology/Biomarker

More information

RANDOMIZED TRIAL ADDRESSING RISK FEATURES AND TIME FACTORS OF SURGERY PLUS RADIOTHERAPY IN ADVANCED HEAD-AND-NECK CANCER

RANDOMIZED TRIAL ADDRESSING RISK FEATURES AND TIME FACTORS OF SURGERY PLUS RADIOTHERAPY IN ADVANCED HEAD-AND-NECK CANCER PII S0360-3016(01)01690-X Int. J. Radiation Oncology Biol. Phys., Vol. 51, No. 3, pp. 571 578, 2001 Copyright 2001 Elsevier Science Inc. Printed in the USA. All rights reserved 0360-3016/01/$ see front

More information

Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón

Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease

More information

USING LOW DOSE RADIATION TO POTENTIATE INDUCTION CHEMOTHER APY IN THE MANAGE- MENT OF LOCALLY ADVANCED HEAD AND NECK MALIGNANCY.

USING LOW DOSE RADIATION TO POTENTIATE INDUCTION CHEMOTHER APY IN THE MANAGE- MENT OF LOCALLY ADVANCED HEAD AND NECK MALIGNANCY. ORIGINAL ARTICLE - RADIATION ONCOLOGY USING LOW DOSE RADIATION TO POTENTIATE INDUCTION CHEMOTHER APY IN THE MANAGE- MENT OF LOCALLY ADVANCED HEAD AND NECK MALIGNANCY C.Sundaresan (1), P.K.Baskar (2), V.Sanjal

More information

Immunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care

Immunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications

More information

Advances in gastric cancer: How to approach localised disease?

Advances in gastric cancer: How to approach localised disease? Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation

More information

The Role of Docetaxel in the Treatment of Head and Neck Cancer

The Role of Docetaxel in the Treatment of Head and Neck Cancer GBMC Head and Neck Conference The Role of Docetaxel in the Treatment of Head and Neck Cancer Simon Best December 7, 2007 Needs assessment: Providers who participate in the care of head and neck cancer

More information

CALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer

CALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000

More information

RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman

RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG

More information

17 th ESO-ESMO Masterclass in clinical Oncology

17 th ESO-ESMO Masterclass in clinical Oncology 17 th ESO-ESMO Masterclass in clinical Oncology Cervical and endometrial Cancer Cristiana Sessa IOSI Bellinzona, Switzerland Berlin, March 28 th, 2018 Presenter Disclosures None Cervical Cancer Estimated

More information

Practice teaching course on head and neck cancer management

Practice teaching course on head and neck cancer management 28-29 October 2016 - Saint-Priest en Jarez, France Practice teaching course on head and neck cancer management IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Nicolas Magné France

More information

Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center

Targeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug

More information

Nasopharyngeal Cancer/Multimodality Treatment

Nasopharyngeal Cancer/Multimodality Treatment Nasopharyngeal Cancer/Multimodality Treatment PANAGIOTIS KATSAOUNIS Medical Oncologist IASO GENERAL HOSPITAL Athens, 22/10/2016 1 st Hellenic Multidisciplinary Conference on Head and Neck Cancer INTRODUCTION

More information

Concurrent Chemo- and Radiotherapy for Ororpharynx Cancer

Concurrent Chemo- and Radiotherapy for Ororpharynx Cancer Concurrent Chemo- and Radiotherapy for Ororpharynx Cancer Faye Johnson MD, PhD Associate Professor Thoracic/Head and Neck Medical Oncology August 2017 Objectives Review data that support concurrent chemo-

More information

Head&Neck, and Thyroid Cancers: Incorporating New Therapies into Current Treatment Algorithms

Head&Neck, and Thyroid Cancers: Incorporating New Therapies into Current Treatment Algorithms Head&Neck, and Thyroid Cancers: Incorporating New Therapies into Current Treatment Algorithms Robert Haddad, MD Disease Center Leader Head and Neck Oncology Program Dana Farber Cancer Institute Harvard

More information

Head & Neck Cancer: When to Irradiate

Head & Neck Cancer: When to Irradiate Head & Neck Cancer: When to Irradiate ESO-ESMO Latin-America 2018 Talented students colleagues 1 > 15 different diseases for RT strategies NC NP OC OP H L 2 HPV Prognostic Marker >2010 Trial Cases Marker

More information

RADIO- AND RADIOCHEMOTHERAPY OF HEAD AND NECK TUMORS. Zoltán Takácsi-Nagy PhD Department of Radiotherapy National Institute of Oncology, Budapest 1.

RADIO- AND RADIOCHEMOTHERAPY OF HEAD AND NECK TUMORS. Zoltán Takácsi-Nagy PhD Department of Radiotherapy National Institute of Oncology, Budapest 1. RADIO- AND RADIOCHEMOTHERAPY OF HEAD AND NECK TUMORS Zoltán Takácsi-Nagy PhD Department of Radiotherapy National Institute of Oncology, Budapest 1. 550 000 NEW PATIENTS/YEAR WITH HEAD AND NECK CANCER ALL

More information

D SCL C OS O UR U E R S

D SCL C OS O UR U E R S HPV-Associated Head and Neck Cancer: Controversies and Challenges NONE DISCLOSURES RESEARCH: Lilly, GSK, MERCK Stuart J. Wong, MD Associate Professor of Medicine and Otolaryngology Medical College of Wisconsin

More information

The Integration and Impact of Modern Radiotherapy Techniques in Clinical Practice. Kian Ang

The Integration and Impact of Modern Radiotherapy Techniques in Clinical Practice. Kian Ang The Integration and Impact of Modern Radiotherapy Techniques in Clinical Practice Kian Ang Funding: P01-CA06294, R01-CA84415, GF Fletcher Chair, Imclone (phase III trial) From Bench to Bedside Head and

More information

REIRRADIATION OF HEAD & NECK TARGETS

REIRRADIATION OF HEAD & NECK TARGETS REIRRADIATION OF HEAD & NECK TARGETS WORKSHOP-Current challenges of patient re-irradiation 6-7 september 2018, Stockholm, Sweden Claes Mercke Karolinska Institute and Karolinska University Hospital STOCKHOLM

More information

Surgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma

Surgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma Surgical Margins in Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma Consensus update and recommendations, 2018 Head and Neck Steering Committee P. Gorphe *, F. Nguyen, Y. Tao, P. Blanchard,

More information

Gynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.

Gynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings. Management of Cervical Cancer in Resource Limited Settings Linus Chuang MD Conflict of Interests None Cervical cancer is the fourth most common malignancy in women worldwide 530,000 new cases per year

More information

Diagnosis and what happens after referral

Diagnosis and what happens after referral Diagnosis and what happens after referral Dr Kate Newbold Consultant in Clinical Oncology The Royal Marsden Women's cancers Breast cancer introduction 1 Treatment Modalities Early stage disease -larynx

More information

Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer

Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm

More information

Medicinae Doctoris. One university. Many futures.

Medicinae Doctoris. One university. Many futures. Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All

More information

State of the art: Standard(s) of radio/chemotherapy for rectal cancer

State of the art: Standard(s) of radio/chemotherapy for rectal cancer State of the art: Standard(s) of radio/chemotherapy for rectal cancer Dr Ian Chau Consultant Medical Oncologist The Royal Marsden Hospital London & Surrey Disclosure Advisory Board: Sanofi Oncology, Eli-

More information

Lung Cancer Epidemiology. AJCC Staging 6 th edition

Lung Cancer Epidemiology. AJCC Staging 6 th edition Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON

More information

Adjuvant chemo- and radiotherapy for poor prognosis head and neck squamous cell carcinomas

Adjuvant chemo- and radiotherapy for poor prognosis head and neck squamous cell carcinomas Critical Reviews in Oncology/Hematology 56 (2005) 353 364 Adjuvant chemo- and radiotherapy for poor prognosis head and neck squamous cell carcinomas Jacques Bernier a,, David G. Pfister b, Jay S. Cooper

More information

Locally advanced disease & challenges in management

Locally advanced disease & challenges in management Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden

More information

HYPERTHERMIA in CERVIX and VAGINA CANCER. J. van der Zee

HYPERTHERMIA in CERVIX and VAGINA CANCER. J. van der Zee HYPERTHERMIA in CERVIX and VAGINA CANCER J. van der Zee ESTRO 2006 Deep hyperthermia in Rotterdam HYPERTHERMIA in CERVIX and VAGINA CANCER ESTRO 2006 Hyperthermia and radiotherapy in primary advanced cervix

More information